echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > HPV vaccine! Merck's Gardasil 9 (Gawei vaccine, 9 price) has been approved by the US FDA to prevent oropharyngeal cancer and other head and neck cancers!

    HPV vaccine! Merck's Gardasil 9 (Gawei vaccine, 9 price) has been approved by the US FDA to prevent oropharyngeal cancer and other head and neck cancers!

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    JUNE 13, 2020 /PRNewswire/ -- Merck and Co recently announced that the U.SFood and Drug Administration (FDA) has approved the HPV vaccine Gardasil 9 (Plus, 9 price) to expand the indications to prevent seven high-risk types of HPV (16, 18, 31, 33, 45, 52, 58) caused by oral pharyose and other head and neck cancersThis oral and head and neck cancer indicationisis is accelerated based on the effectiveness of Gardasil 9 in the prevention of HPV-related genital diseasesThe ongoing approval of the indications may depend on the validation and description of clinical benefits in validation trials, which are currently under wayDr Alain Luxembourg, director of clinical research at the Mercado Research Laboratory, said: "In Mersadon, for more than 20 years, efforts to help prevent certain HPV-related cancers have been a priorityToday's approval to prevent HPV-related pharynx and other head and neck cancers represents a major step forward in Mershadon's mission to help reduce the number of men and women affected by certain HPV-related cancers"Gardasil 9 is a human papillomavirus (HPV) vaccine for women aged 9-45: (1) to prevent cervical, vulva, vagina, anus, pharynx and other cervical cancers caused by seven high-risk types of HPV (16, 18, 31, 33, 45, 52, 58); 2) for the prevention of 9 types of HPV (6, 11, 16, 18, 31, 33, 45, 52, 58) caused by cervical, vulva, vaginal, anal cancer precancerous lesions or abnormal increase of disease; Gardasil 9 for men aged 9-45: (1) to prevent, pharynx and other head and neck cancers caused by 7 types of high-risk HPV (16, 18, 31, 33, 45, 52, 58); Precancerous lesions or abnormal increasein lesions caused by HPV (6, 11, 16, 18, 31, 33, 45, 52, 58); In 2019, Gardasil/Gardasil 9 generated global sales of $3.737 billion, up 19% from the previous yearBoth men and women are at risk of HPV-induced pharynx cancer; For most people, HPV will clean itself upHowever, for those who fail to remove the virus, it can cause certain cancersOral pharynx cancer can be caused by HPV infection in the mouth and throat, which includes the soft palate, the side wall of the throat and the back wall, the tonsils and the back third of the tongueAccording to a recently released model by the Centers for Disease Control and Prevention (CDC), HPV causes more oral cancer than cervical cancer to become the most common HPV-related cancer in the United States(BioValleyBioon.com) Sic: FDA approves Merck's GARDASIL 9 for The Prevention of The Certain HPV-Related Head and Cancers
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.